Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 8/20 | 0.45 |
| ▸ | RXRA | P19793 | 4/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340800 | 0.83 | NPC1 (0.53) | GABRA5NPC1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL29975453 | 0.81 | GRM5 (0.48) | NPC1ALDH1A1CYP2D6CYP2C19GRM5 | |
| SCHEMBL16155558 | 0.76 | SMN1; SMN2 (0.49) | NPC1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL16446308 | 0.76 | RXRA (0.44) | GABRA5ALDH1A1GRM5RXRAGRIN1 | |
| SCHEMBL16446780 | 0.76 | PTGER1 (0.39) | GABRA5ALDH1A1GRM5 | |
| SCHEMBL20195459 | 0.75 | ADORA2A (0.38) | GABRA5NPC1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL26971173 | 0.75 | HTR7 (0.49) | GABRA5 | |
| SCHEMBL27741979 | 0.74 | ALDH1A1 (0.58) | NPC1ALDH1A1CYP2D6CYP2C19GRM5 | |
| SCHEMBL28799362 | 0.74 | NPC1 (0.53) | GABRA5NPC1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL10055039 | 0.74 | NPC1 (0.68) | GABRA5NPC1ALDH1A1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2024-02-01 | — | — | US | disclosed |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11512070-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-3030562-B1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-3030562-B1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-9422285-B2 | Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422285-B2 | Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422285-B2 | Substituted pyrazolo[1,5-A]-pyridine-3-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-23 | — | — | US | disclosed |
| US-20160185775-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160185775-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160185775-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-30 | — | — | US | disclosed |
| EP-3030562-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015018814-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015018814-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512070-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GABRA5 165/4885NPC1 2600/4885ALDH1A1 747/4885 |
| US-20250257052-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GABRA5 165/4885NPC1 2600/4885ALDH1A1 747/4885 |
| US-20160185775-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | PC, AADAC, PDXK | GABRA5 930/4885NPC1 1781/4885ALDH1A1 615/4885 |
| US-12319669-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GABRA5 165/4885NPC1 2600/4885ALDH1A1 747/4885 |
| US-11802121-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GPR119 | GABRA5 165/4885NPC1 2600/4885ALDH1A1 747/4885 |
| US-20240034725-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GABRA5 165/4885NPC1 2600/4885ALDH1A1 747/4885 |
| US-20230124938-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | GABRA5 165/4885NPC1 2600/4885ALDH1A1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.